MiR-152 May Function As an Early Diagnostic and Prognostic Biomarker in Patients with Cervical Intraepithelial Neoplasia and Patients with Cervical Cancer

Overview

Journal Oncol Lett

Specialty Oncology

Date 2019 Jun 13

PMID 31186794

Citations 14

Authors

Dongmei Yang

Qiumei Zhang

Affiliations

Soon will be listed here.

Abstract

Previous studies have demonstrated that circulating miRNAs are effective biomarkers of various types of cancer. It has also been indicated that miR-152 is upregulated in cervical cancer. However, whether miR-152 may be used as an early detection method for patients with cervical cancer is yet to be elucidated. The results of the current study demonstrated that miR-152 levels were the lowest in healthy controls, high in patients with cervical intraepithelial neoplasia (CIN), and the highest in patients with cervical cancer. Furthermore, miR-152 levels in peripheral blood were higher in patients with high-grade CIN compared with those with low-grade CIN. It was also demonstrated that miR-152 levels increased as the clinical stage of cervical cancer advanced. Compared with healthy controls, squamous cell carcinoma antigen (SSC-Ag) levels were significantly higher in patients with cervical cancer. However, no significant differences were identified in patients with CIN, indicating that SCC-Ag could not be used for the early detection of CIN. In contrast, miR-152 was elevated along with SCC-Ag in patients with CIN and cervical cancer. Receiver operating characteristic (ROC) analysis demonstrated that miR-152 preferentially distinguished patients with CIN (95% confidence interval, 0.688-0.973; P<0.001) and patients with cervical cancer (95% confidence interval, 0.817-0.996; P<0.001) from healthy controls. Additionally, miR-152 levels were markedly reduced in patients with cervical cancer who received chemotherapy (28 patients) or chemotherapy and radiation therapy (22 patients). In conclusion, the level of miR-153 in peripheral blood may be utilized as an effective biomarker for the early detection of cervical cancer, thus decreasing the requirement for invasive cervical biopsies. Furthermore, it may be utilized to predict the most effective form of treatment for patients with cervical cancer.

Citing Articles

MicroRNA-Based Liquid Biopsy for Cervical Cancer Diagnostics and Treatment Monitoring.

Kepsha M, Timofeeva A, Chernyshev V, Silachev D, Mezhevitinova E, Sukhikh G Int J Mol Sci. 2025; 25(24.

PMID: 39769036 PMC: 11678179. DOI: 10.3390/ijms252413271.

The diagnostic accuracy of serum and plasma microRNAs in detection of cervical intraepithelial neoplasia and cervical cancer: A systematic review and -analysis.

Ssedyabane F, Obuku E, Namisango E, Ngonzi J, Castro C, Lee H Gynecol Oncol Rep. 2024; 54:101424.

PMID: 38939506 PMC: 11208915. DOI: 10.1016/j.gore.2024.101424.

Performance of an ancillary test for cervical cancer that measures miRNAs and cytokines in serum and cervical mucus.

Fujii T, Nishio E, Tsukamoto T, Kukimoto I, Iwata A Cancer Sci. 2024; 115(8):2795-2807.

PMID: 38749770 PMC: 11309926. DOI: 10.1111/cas.16214.

Expression of miR-152 in cervical cancer and its influence on cisplatin resistance.

Wu J, Chi X, Yang Q, Li J Afr Health Sci. 2024; 23(2):246-255.

PMID: 38223603 PMC: 10782345. DOI: 10.4314/ahs.v23i2.28.

Value of non-coding RNAs to assess lymph node status in cervical cancer.

Dabi Y, Favier A, Razakamanantsoa L, Suisse S, Marie Y, Touboul C Front Oncol. 2023; 13:1144672.

PMID: 37234986 PMC: 10206114. DOI: 10.3389/fonc.2023.1144672.

References

Micke O, Prott F, Schafer U, Tangerding S, Potter R, Willich N . The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer. Anticancer Res. 2001; 20(6D):5113-5. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Hung Y, Shiau Y, Chang W, Kao C, Lin C . Early predicting recurrent cervical cancer with combination of tissue polypeptide specific antigen (TPS) and squamous cell carcinoma antigen (SCC). Neoplasma. 2003; 49(6):415-7. View

Nozawa S, Kojima M, Tukazaki K, Sakayori M, Iizuka R, Kagiyama N . In vitro and in vivo induction of squamous cell carcinoma antigen (SCC) in a uterine cervical cancer cell line (SKG-IIIa) with peplomycin and sodium butyrate. Asia Oceania J Obstet Gynaecol. 1990; 16(2):153-60. DOI: 10.1111/j.1447-0756.1990.tb00018.x. View

Pecorelli S . Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009; 105(2):103-4. DOI: 10.1016/j.ijgo.2009.02.012. View

Zhao S, Yao D, Chen J, Ding N . Circulating miRNA-20a and miRNA-203 for screening lymph node metastasis in early stage cervical cancer. Genet Test Mol Biomarkers. 2013; 17(8):631-6. DOI: 10.1089/gtmb.2013.0085. View

Zhang Z, Meng H, Wang N, Liang L, Liu L, Lu S . Serum microRNA 143 and microRNA 215 as potential biomarkers for the diagnosis of chronic hepatitis and hepatocellular carcinoma. Diagn Pathol. 2014; 9:135. PMC: 4226970. DOI: 10.1186/1746-1596-9-135. View

Dasari S, Wudayagiri R, Valluru L . Cervical cancer: Biomarkers for diagnosis and treatment. Clin Chim Acta. 2015; 445:7-11. DOI: 10.1016/j.cca.2015.03.005. View

Dou H, Wang Y, Su G, Zhao S . Decreased plasma let-7c and miR-152 as noninvasive biomarker for non-small-cell lung cancer. Int J Clin Exp Med. 2015; 8(6):9291-8. PMC: 4538081. View

10.

Tang X, Lin L, Song L, Tang X . Hypoxia-inducible miR-152 suppresses the expression of WNT1 and ERBB3, and inhibits the proliferation of cervical cancer cells. Exp Biol Med (Maywood). 2015; 241(13):1429-37. PMC: 4994918. DOI: 10.1177/1535370215610442. View

11.

Jayasinghe Y, Rangiah C, Gorelik A, Ogilvie G, Wark J, Hartley S . Primary HPV DNA based cervical cancer screening at 25 years: Views of young Australian women aged 16-28 years. J Clin Virol. 2015; 76 Suppl 1:S74-S80. DOI: 10.1016/j.jcv.2015.10.026. View

12.

El-Zein M, Richardson L, Franco E . Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none. J Clin Virol. 2015; 76 Suppl 1:S62-S68. PMC: 4789074. DOI: 10.1016/j.jcv.2015.11.020. View

13.

Lowy D . HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions. J Clin Invest. 2016; 126(1):5-11. PMC: 4701560. DOI: 10.1172/JCI85446. View

14.

Yamashita Y, Uehara T, Hasegawa M, Deng Z, Matayoshi S, Kiyuna A . Squamous cell carcinoma antigen as a diagnostic marker of nasal inverted papilloma. Am J Rhinol Allergy. 2016; 30(2):122-7. DOI: 10.2500/ajra.2016.30.4287. View

15.

Hasahya O, Berggren V, Sematimba D, Nabirye R, Kumakech E . Beliefs, perceptions and health-seeking behaviours in relation to cervical cancer: a qualitative study among women in Uganda following completion of an HPV vaccination campaign. Glob Health Action. 2016; 9:29336. PMC: 4759844. DOI: 10.3402/gha.v9.29336. View

16.

Chen H, Liu H, Zou H, Chen R, Dou Y, Sheng S . Evaluation of Plasma miR-21 and miR-152 as Diagnostic Biomarkers for Common Types of Human Cancers. J Cancer. 2016; 7(5):490-9. PMC: 4780124. DOI: 10.7150/jca.12351. View

17.

Ponomaryova A, Morozkin E, Rykova E, Zaporozhchenko I, Skvortsova T, Dobrodeev A . Dynamic changes in circulating miRNA levels in response to antitumor therapy of lung cancer. Exp Lung Res. 2016; 42(2):95-102. DOI: 10.3109/01902148.2016.1155245. View

18.

Zhao C, Lu F, Chen H, Zhao F, Zhu Z, Zhao X . Clinical significance of circulating miRNA detection in lung cancer. Med Oncol. 2016; 33(5):41. DOI: 10.1007/s12032-016-0757-5. View

19.

Lofters A, Vahabi M . Self-sampling for HPV to enhance uptake of cervical cancer screening: Has the time come in Canada?. CMAJ. 2016; 188(12):853-854. PMC: 5008928. DOI: 10.1503/cmaj.151345. View

20.

Salvatici M, Achilarre M, Sandri M, Boveri S, Vanna Z, Landoni F . Squamous cell carcinoma antigen (SCC-Ag) during follow-up of cervical cancer patients: Role in the early diagnosis of recurrence. Gynecol Oncol. 2016; 142(1):115-119. DOI: 10.1016/j.ygyno.2016.04.029. View